Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics


Nabriva Therapeutics plc - Ordinary Shares (NBRV)

Today's Latest Price: $2.84 USD

0.11 (-3.73%)

Updated Jan 27 8:33am

Add NBRV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NBRV Stock Summary

  • With a price/sales ratio of 153.38, Nabriva Therapeutics plc has a higher such ratio than 97.1% of stocks in our set.
  • As for revenue growth, note that NBRV's revenue has grown -70.84% over the past 12 months; that beats the revenue growth of merely 2.43% of US companies in our set.
  • The volatility of Nabriva Therapeutics plc's share price is greater than that of 97.99% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Nabriva Therapeutics plc are APDN, ICAD, AVGR, MBII, and HTGM.
  • NBRV's SEC filings can be seen here. And to visit Nabriva Therapeutics plc's official web site, go to www.nabriva.com.

NBRV Stock Price Chart Interactive Chart >

Price chart for NBRV

NBRV Price/Volume Stats

Current price $2.84 52-week high $16.50
Prev. close $2.95 52-week low $2.31
Day low $2.84 Volume 16,974
Day high $2.84 Avg. volume 844,063
50-day MA $3.25 Dividend yield N/A
200-day MA $5.66 Market Cap 428.24M

Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio


Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.


NBRV Latest News Stream


Event/Time News Detail
Loading, please wait...

NBRV Latest Social Stream


Loading social stream, please wait...

View Full NBRV Social Stream

Latest NBRV News From Around the Web

Below are the latest news stories about Nabriva Therapeutics plc that investors may wish to consider to help them evaluate NBRV as an investment opportunity.

Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow

The following slide deck was published by Nabriva Therapeutics plc in conjunction with this event....

SA Transcripts on Seeking Alpha | January 16, 2021

Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor conferences in January. * H.C. Wainwright BioConnect Conference being held virtually from January 11-14, 2021. Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update. The Company’s presentation will be available on-demand beginning on Monday, January 11th at 6:00 a.m. Eastern Time (ET). * 2021 ICR Conference being held virtually on Thursday, January 14, 2021. Management will host investor meetings and Mr. ...

Yahoo | January 5, 2021

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

-Amended agreement encompasses enhanced manufacturing collaboration and regulatory support -Accelerates milestone payments to Nabriva, including fourth quarter 2020 payment of $1 millionDUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the restructuring of its license agreement with Sinovant Sciences for XENLETA™ (lefamulin) in the greater China region. The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China. The restructured...

Yahoo | December 7, 2020

The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for t...

Benzinga | December 3, 2020

Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split

DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Global Select Market as of the commencement of trading on December 3, 2020. At the Annual General Meeting of Shareholders on July 29, 2020, Nabriva Therapeutics’ shareholders approved, subject to and conditional upon the Board of Directors of Nabriva Therapeutics determining, in its sole discretion, that a reverse stock split is necessary for the Company to comply with the minimum $1.00 per share ...

Yahoo | December 2, 2020

Read More 'NBRV' Stories Here

NBRV Price Returns

1-mo 10.08%
3-mo -44.31%
6-mo -62.63%
1-year -79.12%
3-year -95.75%
5-year -96.65%
YTD 17.36%
2020 -81.67%
2019 -9.59%
2018 -75.59%
2017 0.34%
2016 -38.05%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7765 seconds.